Aims: To compare quality of life (QoL) and factors associated with QoL change after retropubic (RMUS) and transobturator midurethral slings (TMUS) using the Incontinence Impact Questionnaire (IIQ) and the International Consultation on Incontinence Questionnaire (ICIQ).
U rinary incontinence (UI) is a global problem with a significant negative impact on quality of life. 1 Although prevalence rates vary depending on the definition of UI and the age of subjects, a recent systematic review of population-based studies reported rates from 16.2% to 69.2%. 1 Quality-of-life (QoL) assessment is increasingly important in patient care and as an outcome in treatment trials. A variety of condition-specific QoL instruments is available for use for UI without consensus of superiority.
Other investigators reported that age, severity and type of UI, number of UI episodes, body weight, stress, and help-seeking behavior were significantly associated with lower QoL in women with stress urinary incontinence (SUI) seeking surgical intervention. 2 We previously analyzed baseline data from the cohort of 597 women enrolled in the trial of midurethral slings (TOMUS) and found that lower QoL was associated with non-UI factors such as younger age and higher body mass index (BMI) as well as type and severity of UI symptoms. 3 The objective of this paper was to assess the improvement in UI-related QoL in women after retropubic midurethral sling (RMUS) and transobturator midurethral sling (TMUS) for stress urinary incontinence SUI using 2 measures, the Incontinence Impact Questionnaire (IIQ) 4 and the International Consultation on Incontinence Questionnaire (ICIQ). 5 A secondary objective was to compare the 2 instruments by identifying those clinical and demographic factors associated with change in each measure.
MATERIALS AND METHODS

Participants
We analyzed data from a randomized trial of women undergoing SUI surgery conducted by the Urinary Incontinence Treatment Network (UITN). The TOMUS (N = 597) compared RMUS versus TMUS for SUI. 6 The methodology and outcomes of this trial are published. 6 Eligibility criteria included a combination of self-reported symptoms and clinical examination measures. Self-reported SUI symptoms included duration of SUI symptoms of more than 3 months, and a Medical, Epidemiologic, and Social Aspects of Aging questionnaire 7 (MESA) SUI symptom index greater than the MESA urge incontinence symptom index. Eligibility required a positive provocative stress test at a standardized bladder volume of 300 mL. The trial allowed concomitant vaginal surgeries. All participants provided written informed consent, and each local institutional review board reviewed and approved the study protocols.
Measures
The outcome of interest was change in QoL after surgery. We used 2 condition-specific measures of QoL: the ICIQ and the IIQ. 4, 5, 8 The ICIQ assessed the impact of UI on everyday life; whereas the IIQ assessed the impact of UI on various activities, roles, and emotional states.
Potential predictors of QoL included treatment success, demographic and clinical characteristics, and a range of patientreported assessments of UI symptom severity, improvement after surgery, and postoperative pain that were considered potential (Table 1 ). 9Y11 Treatment success was measured by a composite that included both subjective and objective measures of UI: the absence of stresstype symptoms on the MESA questionnaire, 9 no leakage on the 3-day voiding diary, a negative provocative stress test, a nega-tive 24-hour pad test, and no retreatment (behavioral, pharmacological, or surgical) for SUI. 6 Definitions of clinical terms and methods of evaluation of participants were uniform across all sites and adhered to standards set by the International Continence Society. *Voiding dysfunction is defined as a complication if one of the following criteria are met: (1) uses a catheter to facilitate bladder emptying at or beyond the 6-week visit or (2) has undergone medical therapy to facilitate bladder emptying at or beyond the 6-week visit or (3) has undergone surgical therapy to facilitate bladder emptying at anytime after TOMUS surgery.
†Pain is defined as a complication if the following criteria are met at or beyond the 6-week visit: (1) patient answers ''yes'' to the introductory stem question ''Have you had any pain within the last 24 hours as a result of your incontinence operation?'' and (2) 
Data Analysis
Continuous variables are reported with mean (SD) and range, whereas categorical variables are presented with frequency and percent.
We first evaluated the change over time in QoL (IIQ and ICIQ) using repeated-measures analysis of variance controlling for time (6, 12 , and 24 months), treatment group, interaction of time and treatment, as well as the baseline value.
This analysis showed that there was minimal change in QoL scores between 12 and 24 months ( Fig. 1) . Therefore, to maximize the cases with available data, we analyzed predictors of change in QoL between baseline and 12 months. Based on data in Figure 1 , we assume that the results at 24 months would be similar. To determine the association of clinical and demographic factors with UI-related QoL, we computed a bivariate regression analysis of each potential predictor on change in IIQ or ICIQ. We then computed a multiple regression analysis that included all variables-associated bivariately with change in IIQ or ICIQ at P G 0.20. In the final models, we removed variables that were no longer statistically significant at P = 0.05. Treatment group and baseline values of the variables were included in all models.
Analyses were performed using SAS version 9.2 (SAS Institute, Inc, Cary, NC). A 5% 2-sided significance level was used for all statistical testing. Figure 1 displays mean IIQ and ICIQ values at each study visit by treatment group. The change from baseline to follow-up was substantial in both groups, but the change over time after surgery was minimal and statistically significant for ICIQ (P = 0.03) but not for IIQ (P = 0.35). The difference between the treatment groups was not statistically significant for either IIQ (P = 0.66) or ICIQ (P = 0.51). The analytical sample consisted of 527 participants, excluding 70 women who had not completed the 12-month survey. To check for response bias, we compared those who completed the survey (n = 527) to those who did not (n = 70) on selected characteristics (not shown). Responders were similar to nonresponders on all characteristics except that responders were slightly older (53.6 vs 47.3 years; P G 0.0001). Importantly, they were similar with regard to baseline UI severity and QoL.
RESULTS
Sample Characteristics
The 527 women in this analysis were predominantly white (80%) and middle-aged (mean [SD], 53.6 [10.8.0] years) yet socioeconomically diverse. By trial design, they all had stress UI (mean [SD] MESA stress index, 71.8 [17.2] ), but many also reported some urge UI (mean [SD] MESA urge index, 35.2 [21.8]).
More than half (58%) reported prior treatment for UI and concomitant anal incontinence (59%). Mean body mass index (BMI) was 30.1 (6.6) kg/m 2 . Women randomized to the 2 MUS approaches did not differ on the characteristics at baseline or at 12 months after surgery ( Table 1) .
Changes in Quality of Life
The mean (SD) change from baseline to 12 months in the IIQ was a decrease of 129 (96.1) points (P G 0.0001). Similarly, the mean (SD) change in the ICIQ was a decrease of 10.3 (5.0) points (P = 0.001). Four hundred fifty-nine women (90%) reported that they were ''much better'' or very much better'' on the Patient Global Impression of Improvement Scale at 12 months. Results of the multivariable analyses are displayed in Table 2 . Quality-of-life improvement measured by change in IIQ was associated with treatment success, younger age, improvement in SUI symptom severity, and improvement in symptom bother, explaining 84% of the variability in QoL. Quality-of-life improvement measured by change in ICIQ was similarly associated with treatment success (P G 0.001), younger age (P = 0.001), improvement in SUI symptom severity (P G 0.001), improvement in symptom bother (P G 0.001), lower baseline BMI (P = 0.02), and no reoperation for SUI in 12 months (P = 0.009), explaining 76% of the variability in change in QoL.
DISCUSSION
This study shows that condition-specific QoL improves after midurethral sling surgery, regardless of approach (RMUS or TMUS) or QoL measure. It should be reassuring to surgeons and patients alike that after midurethral sling surgery for SUI, patients report approximately 80% improvement in QoL that is sustained for at least 2 years. Women with the greatest QoL improvement were younger, reported more improvement in UI symptom bother, and had successful surgery. These data should be integral in counseling women before midurethral sling surgery for SUI.
This analysis reinforces our understanding of the importance of patient-reported outcomes for minimally invasive continence surgery. This study offered a unique opportunity to compare predictors of QoL change using the ICIQ and the IIQ. The fact that reductions in scores (or improvement in QoL) were similar for both measures (77% for ICIQ and 85% for IIQ at 1 year) should be reassuring to clinicians and clinical researchers. Data from this study are consistent with prior findings that QoL after SUI surgery is observed after a variety of surgical approaches including Burch retropubic urethropexy, traditional sling operations, and midurethral slings. Most reports support approximately a 70% to 80% improvement that is sustained over time. 2, 12, 13 Analysis of the SISTEr trial comparing Burch versus sling showed a 78% improvement after both procedures, maintained up to 2 years. 12 Our data are also consistent with large international trials demonstrating similar improvements in QoL after RMUS and TMUS. 2, 14, 15 Porena et al 14 used the IIQ-7 to assess QoL changes and found no differences between the RMUS and TMUS procedures, with scores decreasing from 8 to zero at 1 year. Meschia et al 16 used the ICIQ to assess improvements in QoL, also showing 80% to 85% improvements in overall scores.
Measuring QoL with different instruments poses some challenges, namely, which is the better tool to assess patient-oriented outcomes? The ICIQ is a brief 3-scored and 1-unscored selfdiagnostic item that assesses the prevalence, frequency and volume of leakage, as well as the QoL impact. 5 The ICIQ demonstrates good construct validity and reliability and high correlation with the Sandvik severity index. 17, 18 In this study, the ICIQ score improved from 13 to 3 after midurethral sling surgery and although there was a statistically significant ''deterioration'' of the ICIQ score from 2.9 to 3.4 at 24 months this is unlikely to represent a clinically relevant finding. The observed deterioration in the ICIQ score at 24 months could be related to the older age of the responders at 12 months, as younger women reported significantly greater improvement in QoL. A similar deterioration in IIQ scores was not observed. Finally, whereas there are no published data on ICIQ minimum important differences, and since both the 12-and 24-month ICIQ scores remain below 4, it would seem that any leakage reported remains quite low.
This study used the IIQ long form, developed as a conditionspecific tool to assess the impact of UI on QoL. 4 Thirty questions measure the effect of UI on daily activities within 4 subscales of physical activity, travel, social/relationships, and emotional health. The subscale scores are summed for a total score from zero to 400, with higher scores representing more negative impact on QoL. This scale exclusively measures impact on QoL, unlike the ICIQ, which includes frequency and severity of UI of nearly half of the total score. Whereas there is no published data on the minimum important difference for the IIQ long form, we observed no difference between RMUS or TMUS with this tool, and the response was durable to 2 years.
Interestingly, the models predicting change in QoL as measured by the IIQ identified younger age but also more surgically modifiable UI factors, specifically, treatment success, symptom severity, and symptom bother. In addition, these factors explained more of the variability in QoL improvement after surgery. Improvement in the ICIQ was associated not only with improvement in UI-related symptom severity and bother but also with the unrelated nonmodifiable UI factors of lower BMI and no reoperation in the first year. This finding that the IIQ is responsive to more UI-related outcomes provides support for use of the IIQ to measure QoL in surgical studies.
Predictors of improved QoL after surgery for SUI in the SISTEr study were decreased UI bother, improved severity, and younger age, as well as Hispanic ethnicity and assigned treatment (having had a Burch). 2 In this study, ethnicity and assigned treatment were not predictive of improved QoL. Although the samples for both the SISTEr and TOMUS trials were composed of approximately 11% Hispanic women, it is unclear why ethnicity was not an important predictive factor in the TOMUS population. That assigned treatment was not related to QoL improvement in this study may reflect the similar nature, success, and complication rates (ie, urinary retention) between the 2 midurethral sling procedures and a lack of statistical power.
Strengths of this study include the prospective multicenter randomized design of the trial using 2 different validated condition-specific measures of QoL. Limitations of this study include the lack of available information on the IIQ and ICIQ minimum important difference to inform clinically meaningful differences and changes over time.
In conclusion, women undergoing either RMUS or TMUS for SUI can expect similar substantial improvements in conditionspecific QoL sustained over at least 2 years. Whereas many factors are associated with postoperative QoL improvement as measured with both the IIQ and ICIQ, the IIQ was associated with more direct UI-related factors than was the ICIQ, and may be the preferred tool for SUI surgical studies.
